

ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)
SCHEDULE OF INVESTMENTS (Unaudited)
December 31, 2023

Shares		Fair Value
	COMMON STOCKS — 87.7%	
	BIOTECH & PHARMA - 77.4%	
267,500	Abivax S.A. - ADR ^(a)	\$ 2,862,250
26,000	ACADIA Pharmaceuticals, Inc. ^(a)	814,060
140,000	Amicus Therapeutics, Inc. ^(a)	1,986,600
151,000	Amylyx Pharmaceuticals, Inc. ^(a)	2,222,720
7,750	Argenx S.E. - ADR ^(a)	2,948,333
50,000	Aurinia Pharmaceuticals, Inc. ^(a)	449,500
7,500	BeiGene Ltd. - ADR ^(a)	1,352,700
90,000	Bicycle Therapeutics plc - ADR ^(a)	1,627,200
675,000	BioCryst Pharmaceuticals, Inc. ^(a)	4,043,250
14,000	BioMarin Pharmaceutical, Inc. ^(a)	1,349,880
25,000	Cerevel Therapeutics Holdings, Inc. ^(a)	1,060,000
1,000,000	Coherus Biosciences, Inc. ^(a)	3,330,000
10,000	Cymabay Therapeutics, Inc. ^(a)	236,200
112,500	Deciphera Pharmaceuticals, Inc. ^(a)	1,814,625
100,000	Dynavax Technologies Corporation ^(a)	1,398,000
105,000	Galapagos N.V. - ADR ^(a)	4,268,250
8,500	Gilead Sciences, Inc.	688,585
35,000	GSK plc - ADR	1,297,100
122,000	Harmony Biosciences Holdings, Inc. ^(a)	3,940,600
127,500	ImmunoGen, Inc. ^(a)	3,780,375
38,000	Immunovant, Inc. ^(a)	1,600,940
20,000	Intra-Cellular Therapies, Inc. ^(a)	1,432,400
245,000	Ironwood Pharmaceuticals, Inc. ^(a)	2,802,800
10,500	Jazz Pharmaceuticals plc ^(a)	1,291,500
137,000	KalVista Pharmaceuticals, Inc. ^(a)	1,678,250
3,500	Karuna Therapeutics, Inc. ^(a)	1,107,785
1,125,000	Karyopharm Therapeutics, Inc. ^(a)	973,125
50,000	Mirum Pharmaceuticals, Inc. ^(a)	1,476,000
450,000	Nuvation Bio, Inc. ^(a)	679,500
117,500	Pacira BioSciences, Inc. ^(a)	3,964,450
80,000	Pfizer, Inc.	2,303,200
30,000	Protagonist Therapeutics, Inc. ^(a)	687,900
220,000	Revance Therapeutics, Inc. ^(a)	1,933,800
16,000	Roche Holding A.G. - ADR	579,680

ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)
SCHEDULE OF INVESTMENTS (Unaudited) (Continued)
December 31, 2023

Shares		Fair Value
	COMMON STOCKS — 87.7% (Continued)	
	BIOTECH & PHARMA - 77.4% (Continued)	
55,000	Roivant Sciences Ltd. ^(a)	\$ 617,650
40,000	Royalty Pharma plc, Class A	1,123,600
30,000	Structure Therapeutics, Inc. - ADR ^(a)	1,222,800
421,025	uniQure N.V. ^(a)	2,850,339
18,000	United Therapeutics Corporation ^(a)	3,958,020
155,000	UroGen Pharma Ltd. ^(a)	2,325,000
34,298	Valneva S.E. - ADR ^(a)	352,926
10,000	Ventyx Biosciences, Inc. ^(a)	24,700
150,000	Verastem, Inc. ^(a)	1,221,000
56,000	Verona Pharma plc - ADR ^(a)	1,113,280
35,000	Viatrix, Inc.	379,050
668,151	VYNE Therapeutics, Inc. ^(a)	1,556,792
		<u>80,726,715</u>
	HEALTH CARE FACILITIES & SERVICES - 1.7%	
310,000	DocGo, Inc. ^(a)	1,732,900
	MEDICAL EQUIPMENT & DEVICES - 5.6%	
200,000	Embecta Corporation	3,786,000
5,000	Inari Medical, Inc. ^(a)	324,600
20,500	Medtronic PLC	1,688,790
		<u>5,799,390</u>
	RETAIL - CONSUMER STAPLES - 3.0%	
120,000	Walgreens Boots Alliance, Inc.	3,133,200
	TOTAL COMMON STOCKS (Cost \$95,132,528)	<u>91,392,205</u>
	RIGHT — 0.0%^(b)	
	BIOTECH & PHARMA - 0.0%^(b)	
300,000	Amryt Pharma, PLC. – CVR ^{(a) (d) (e)}	Expiration Date Exercise Price 12/31/2024 \$ 0.50 –
300,000	Amryt Pharma, PLC. – CVR ^{(a) (d) (e)}	12/31/2024 \$ 0.50 –
	TOTAL RIGHT (Cost \$0)	<u>–</u>

ALPHACENTRIC LIFESCI HEALTHCARE FUND (LYFAX, LYFCX, LYFIX)
SCHEDULE OF INVESTMENTS (Unaudited) (Continued)
December 31, 2023

Shares		Fair Value
	SHORT-TERM INVESTMENTS — 11.3%	
	MONEY MARKET FUNDS - 11.3%	
1	Fidelity Money Market Government Portfolio, Class I, 5.24% ^(c)	\$ 1
11,786,585	First American Treasury Obligations Fund, Class X, 5.28% ^(c)	11,786,585
	TOTAL MONEY MARKET FUNDS (Cost \$11,786,586)	11,786,586
	TOTAL INVESTMENTS - 99.0% (Cost \$106,919,114)	\$ 103,178,791
	OTHER ASSETS IN EXCESS OF LIABILITIES - 1.0%	1,052,395
	NET ASSETS - 100.0%	\$ 104,231,186

ADR - American Depositary Receipt

CVR - Contingent Value Right

LTD - Limited Company

NV - Naamioze Vennootschap

PLC - Public Limited Company

S/A - Société Anonyme

^(a) Non-income producing security.

^(b) Percentage rounds to less than 0.1%.

^(c) Rate disclosed is the seven day effective yield as of December 31, 2023.

^(d) Illiquid security. The total fair value of these securities as of December 31, 2023 was \$0, representing 0.0% of net assets.

^(e) Fair Valued by the Board of Trustees in good faith using significant unobservable inputs.